Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Orion Oyj

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
From Orion Oyj
Via GlobeNewswire
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
From Orion Oyj
Via GlobeNewswire
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
From Orion Oyj
Via GlobeNewswire
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
From Orion Oyj
Via GlobeNewswire
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
From Orion Oyj
Via GlobeNewswire
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Orion Oyj
Via GlobeNewswire
Orion is developing the Finnish life science industry in a unique collaboration project
From Orion Oyj
Via GlobeNewswire
Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
From Orion Oyj
Via GlobeNewswire
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
From Orion Oyj
Via GlobeNewswire
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
From Orion Oyj
Via GlobeNewswire
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
From Orion Oyj
Via GlobeNewswire
Orion Research Foundation grants EUR 1,112,000 for research in 2024
From Orion Oyj
Via GlobeNewswire
European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder
From Orion Oyj
Via GlobeNewswire
Orion and Bayer expand clinical development program for darolutamide in prostate cancer
From Orion Oyj
Via GlobeNewswire
Darolutamide approved for additional prostate cancer indication in China
From Orion Oyj
Via GlobeNewswire
Darolutamide receives EU approval for additional indication in prostate cancer
From Orion Oyj
Via GlobeNewswire
Darolutamide receives approval for additional prostate cancer indication in Japan
From Orion Oyj
Via GlobeNewswire
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
From Orion Oyj
Via GlobeNewswire
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand
From Orion Oyj
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.